About: http://data.cimple.eu/news-article/bf3add4776ae2f4a163f10dee1aa2e8878d5bb620ae1ed5af01dd8c1

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/bf3add4776ae2f4a163f10dee1aa2e8878d5bb620ae1ed5af01dd8c1 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Swiss pharmaceuticals giant Novartis has decided to halt a clinical trial of hydroxychloroquine as a treatment for COVID-19, citing problems in recruiting enough patients for the study of the controversial drug. "Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrolment challenges that have made trial completion infeasible," the company said in a statement late Friday. This problem "made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe," it said. "No safety issues have been reported, and there are no conclusions on efficacy from the study." Hydroxychloroquine and its related compound chloroquine have traditionally been used to treat malaria and with a known anti-viral potential was seen as a possible treatment in the early days of the pandemic. Despite recognised serious side effects, many prominent figures, including US President Donald Trump, touted it widely as a COVID-19 treatment at a time when there is no vaccine for the disease and other potentially effective drugs are only just beginning to be identified. In April, Novartis said it would sponsor a Phase III clinical trial of around 440 patients in the US using hydroxychloroquine to treat patients hospitalised with COVID-19 in agreement with the US Food and Drug Administration (FDA). But earlier this month, the US authorities suspended its use and this week the World Health Organization said it was suspending its trials of hydroxychloroquine because it showed no ability to reduce mortality rates. apo/at/bmm/bp
schema:headline	Swiss giant Novartis halts COVID-19 hydroxychloroquine study
schema:mentions	Phases of clinical research Novartis Clinical trial Malaria Chloroquine Mortality rate Hydroxychloroquine Switzerland World Health Organization Food and Drug Administration Pandemic Vaccine President of the United States Donald Trump Coronavirus disease 2019 Friday Night Videos
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-06-20 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	92 (xsd:integer)
http://data.cimple...entionsConspiracy	suppressed cures conspiracy theory

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software